Home » Boston Scientific Submits Final Modules to FDA for Approval of Stents
Boston Scientific Submits Final Modules to FDA for Approval of Stents
Boston Scientific Corporation announced that it has submitted to the U.S. Food and Drug Administration the final modules of the Company’s Pre-Market Approval applications for both its TAXUS Liberte Atom Paclitaxel-Eluting Coronary Stent System and its TAXUS Liberte Long Paclitaxel-Eluting Coronary Stent System.
TradingMarkets
TradingMarkets
Upcoming Events
-
07May
-
14May
-
30May